Recruiting

Testing a new drug combined with chemotherapy for advanced pancreatic cancer

Plain-English translation of NCT06962267 on ClinicalTrials.gov ↗ · Source last updated May 2025 · Translation generated June 2026 · How we translate trials

Read our Pancreatic Cancer research guide →

Phase 2 — Testing in a bigger group (up to a few hundred people) to see if the treatment actually works and is still safe.

What is this trial?

This trial is testing a new medication called TQB2916 given together with two drugs (gemcitabine and albumin-paclitaxel) to treat pancreatic cancer that has spread beyond the pancreas. The study wants to see if this combination is safe and effective when used as the very first treatment for this type of cancer. Researchers are enrolling about 50 patients to find out how well this medication works.

Pancreatic cancer that has spread is very serious, and current first-line treatments have limited effectiveness. This trial is testing whether adding this new medication to standard might help patients live longer and improve outcomes.

Do you qualify?

You likely qualify if…

you are between 18 and 75 years old
you have been diagnosed with pancreatic ductal adenocarcinoma (confirmed by a biopsy or tissue sample)
you have cancer that has spread to other parts of your body and can be measured on imaging
you have not received any prior chemotherapy or cancer treatment
you are in good enough overall health to tolerate treatment (ECOG score 0–1)
you are able to use reliable birth control during and for 6 months after the study

You likely don't qualify if…

you have had another type of cancer in the past 5 years (with some exceptions for early-stage cancers)
you have serious side effects from previous treatments that haven't resolved
you have had major surgery, a serious injury, or an unhealed wound within the past 4 weeks
you have had a blood clot or stroke within the past 6 months
you have untreated or unstable hepatitis B or C infection, or active syphilis

What participation looks like

You would receive the new medication combined with through regular clinic visits, with each treatment cycle lasting 28 days. You'll have blood tests and imaging scans to monitor how well the treatment is working and watch for side effects. The study will track your health and cancer response over time to determine whether this combination is safe and beneficial for patients with advanced pancreatic cancer.

AI-generated summary from trial data · Jun 15, 2026 · Not medical advice

Trial locations(1 site)

China

Peking Union Medical College Hospital, Chinese Academy of Medical Sciences, Beijing, Beijing Municipality